Understand the source comparison
GHK-Cu versus BPC-157 in fibrosis: complementary ECM remodelling mechanisms
GHK-Cu and BPC-157 both target ECM remodelling in liver fibrosis but through mechanistically distinct pathways that are potentially additive. GHK-Cu primarily addresses the oxidative stress-HSC activation axis (Nrf2-ROS suppression → reduced HSC transdifferent
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHK-Cu and BPC-157 both target ECM remodelling in liver fibrosis but through mechanistically distinct pathways that are potentially additive. GHK-Cu primarily addresses the oxidative stress-HSC activation axis (Nrf2-ROS suppression → reduced HSC transdifferentiation trigger) and promotes MMP-2/9 upregulation for collagen dissolution. BPC-157 primarily addresses the TGF-β1-Smad2/3 signalling axis (HSC transdifferentiation signalling suppression) and MMP-13 upregulation for fibrillar collagen degradation, while reducing TIMP-1-mediated MMP inhibition. Together, they target different phases of the fibrogenic cascade and different MMP isoforms — GHK-Cu targeting the gelatinases (MMP-2/9) that degrade denatured basement membrane collagen, BPC-157 targeting collagenase (MMP-13) that cleaves native fibrillar collagen I/II/III.
- A research design combining GHK-Cu and BPC-157 at their respective mechanistic doses, with measurement of MMP isoform activities (gelatin zymography for MMP-2/9, fluorescent peptide substrate assay for MMP-13) alongside global Sirius Red quantification and hydroxyproline content, would provide the first mechanistic evidence that these two complementary ECM remodelling pathways are indeed additive. This experiment has not, to our knowledge, been published — representing a genuine gap in the preclinical fibrosis literature.